Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC

The University of Texas System (UT)

Status: Completed

Conditions: Hepatocellular Carcinoma

Treatments: Drug: Lipiodol

Study type: Observational

Funder types: Other

Identifiers

NCT04459468

STU-2019-1758

Details and patient eligibility

About

This study will enroll patients with hepatocellular carcinoma being planned for TACE or other standard of care treatment (such as denovo ablation or Y90) and obtain blood samples pre and post treatment procedure for biomarker identification using bead based X-aptamer library. No intervention is planned.

Full description

This is a prospective, non-blinded, multi-arm study. Patients at 18 - 70 years old with liver cancer will be enrolled.

The approach is to identify novel proteomic biomarkers for HCC patients treated with Lipiodol TACE, denovo ablation or Y90 using beads-based X-aptamer library, then validate and create a biomarker panel that can be used to predict the outcome of HCC post treatment.

Lipiodol TACE, denovo ablation, or Y90 will be done as standard of care and the only thing done as research will be blood draws pre and post-TACE.

Enrollment: 17 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Ability to understand and the willingness to sign a written informed consent.
2. Male or female aged 18-70years.
3. Diagnosed with primary or metastatic liver cancer.
4. Scheduled to undergo Lipoidal TACE, denovo ablation, or Yttrium-90 (Y90) radioembolization as part of standard of care.

Exclusion criteria

Subjects who have received chemotherapy, radiation or surgery for HCC.

Trial design

17 participants in 3 patient groups

HCC for Lipiodol TACE, denovo ablation, or Y90 radioembolization

Description:

These patients will receive standard of care Lipiodol TACE, denovo ablation, or Y90 radioembolization treatment. No research intervention is planned.

Treatment:

Drug: Lipiodol

Healthy controls

Description:

Healthy controls from public database

HCC patients

Description:

HCC patients will be used for biomarker validation.